{"id":"ach-0144471","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4250860","moleculeType":"Small molecule","molecularWeight":"580.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD40 is a costimulatory molecule that plays a key role in the activation of immune cells. By targeting CD40, ACH-0144471 aims to modulate the immune response and potentially treat various autoimmune and inflammatory conditions.","oneSentence":"ACH-0144471 is a monoclonal antibody targeting the CD40 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:44.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT05389449","phase":"PHASE3","title":"A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-10-28","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT03472885","phase":"PHASE2","title":"Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-05-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":12},{"nctId":"NCT03459443","phase":"PHASE2","title":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-06-20","conditions":"C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis","enrollment":22},{"nctId":"NCT03181633","phase":"PHASE2","title":"A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-06-22","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":8},{"nctId":"NCT04551599","phase":"PHASE1","title":"A Study of the Effects of Food and Age on Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-02-21","conditions":"Healthy","enrollment":27},{"nctId":"NCT03369236","phase":"PHASE2","title":"A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-06-12","conditions":"C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease","enrollment":13},{"nctId":"NCT03053102","phase":"PHASE2","title":"Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-03-31","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":10},{"nctId":"NCT04609696","phase":"PHASE1","title":"Study of the Metabolism of Danicopan in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-10-20","conditions":"Healthy","enrollment":24},{"nctId":"NCT03723512","phase":"NA","title":"Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-06","conditions":"C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis","enrollment":7},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT03124368","phase":"PHASE2","title":"A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-08-09","conditions":"C3 Glomerulonephritis, Dense Deposit Disease, C3 Glomerulopathy","enrollment":6},{"nctId":"NCT05016206","phase":"PHASE1","title":"A Study of the Cardiac Effects of Danicopan in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-26","conditions":"Healthy","enrollment":33},{"nctId":"NCT03384186","phase":"PHASE1","title":"A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-12-01","conditions":"Healthy","enrollment":14},{"nctId":"NCT03555539","phase":"PHASE1","title":"Study of Danicopan in Participants With Hepatic Impairment","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-05-01","conditions":"Hepatic Impairment","enrollment":16},{"nctId":"NCT04940559","phase":"PHASE1","title":"Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-08-02","conditions":"Healthy","enrollment":26},{"nctId":"NCT03108274","phase":"PHASE1","title":"A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-04-18","conditions":"Healthy","enrollment":35},{"nctId":"NCT04935294","phase":"PHASE1","title":"Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-01-24","conditions":"Healthy, Renal Dysfunction","enrollment":16},{"nctId":"NCT04889690","phase":"PHASE1","title":"Study of Multiple Doses of Danicopan in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-05-21","conditions":"Healthy","enrollment":45},{"nctId":"NCT04889391","phase":"PHASE1","title":"Study of Radiolabeled Danicopan in Healthy Male Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-09-14","conditions":"Healthy","enrollment":8},{"nctId":"NCT04889677","phase":"PHASE1","title":"Study of a Single Dose of Danicopan in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-02-04","conditions":"Healthy","enrollment":44},{"nctId":"NCT04451434","phase":"PHASE1","title":"Study of Danicopan in Participants of Japanese Descent","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-17","conditions":"Healthy","enrollment":9},{"nctId":"NCT04709094","phase":"PHASE1","title":"A Drug Interaction Study of Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-28","conditions":"Healthy","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACH-0144471","genericName":"ACH-0144471","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACH-0144471 is a monoclonal antibody targeting the CD40 receptor. Used for Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}